

Caroline Lascoux-Combe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8162437/publications.pdf>

Version: 2024-02-01

12
papers

374
citations

1307594

7
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

512
citing authors

#	ARTICLE	IF	CITATIONS
1	Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. <i>Journal of Hepatology</i> , 2016, 65, 683-691.	3.7	84
2	The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	2.9	19
3	Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. <i>Journal of Hepatology</i> , 2009, 50, 1074-1083.	3.7	63
4	Rates and determinants of hepatitis B α ™ antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfecting with HIV and hepatitis B virus. <i>Aids</i> , 2015, 29, 1963-1973.	2.2	42
5	High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. <i>Hepatology</i> , 2013, 58, 912-922.	7.3	37
6	Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV α ™HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study. <i>Journal of the International AIDS Society</i> , 2017, 20, 21426.	3.0	37
7	Kinetics of Hepatitis B Core α ™Related Antigen and Anti α ™Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus α ™Hepatitis B Coinfection. <i>Journal of Infectious Diseases</i> , 2020, 221, 1826-1837.	4.0	8
8	Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e24731.	1.0	6
9	Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients. <i>Antiviral Research</i> , 2018, 149, 174-178.	4.1	4
10	Profiles of liver fibrosis evolution during long α ™term tenofovir treatment in HIV α ™positive patients coinfecting with hepatitis B. <i>Liver International</i> , 2021, 41, 2874-2884.	3.9	4
11	Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus α ™Hepatitis B Virus α ™Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort. <i>Clinical Infectious Diseases</i> , 2022, 74, 1012-1021.	5.8	4
12	Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3009-3019.	3.0	4